Diabetes drug sitagliptin shows no increased risk of heart events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1Ge2MXh